

**ASX Announcement** 

11 November 2025

Bioxyne releases Australian made GMP MDMA capsules for supply to Clinical Trials in Victoria and to Authorised Prescriber dispensing in Queensland

Bioxyne Limited (ASX: BXN) (Bioxyne or Company), through its wholly owned subsidiary Breathe Life Sciences (BLS), is pleased to announce the fulfilment of two standing Purchase Orders for the supply of GMP Manufactured MDMA capsules (BLSMD40) for the treatment of Post-Traumatic Stress Disorder (PTSD) in Australia.

# **Key Highlights:**

- Breathe Life Sciences (BLS) is Australia's first TGA GMP licensed pharmaceutical manufacturer of psychedelic and psychoactive medicines.
- BLS has manufactured and released for supply BLSMD40 capsules which meet Australian and international pharmaceutical standards.
- BLSMD40 capsules are being supplied to clinical trials in Victoria and authorized prescribers (psychiatrists) providing psychedelic therapy assisted services in Queensland
- BLSMD40 is an investigational medicine designed for treatment resistant posttraumatic stress disorder (PTSD) supplied via Australia's Authorised Prescriber pathway for MDMA-assisted therapy.
- Initial purchase order supply volumes will surpass 400 patient doses.

#### **Market Insights:**

PTSD Prevalence in Australia: Approximately 12% of Australians experience PTSD during their lifetime, highlighting a significant need for effective treatments<sup>1</sup>.


Global Psychedelic Drugs Market: The global psychedelic drugs market is projected to grow to AUD 14 billion by 2032, reflecting increasing acceptance and demand for psychedelic-assisted therapies<sup>2</sup>.

## Strategic Significance:

The fulfilment of these orders position Bioxyne at the forefront of innovative mental health treatments in Australia. By leveraging Bioxyne's manufacturing capabilities the mental health sector in Australia can now source high quality Australian made GMP compliant medication for patients suffering from PTSD.

<sup>&</sup>lt;sup>2</sup> Zion Market Research







<sup>&</sup>lt;sup>1</sup> <u>ChoosingTherapy.com+12Market Research Future+12PMC+12</u>



### **About Bioxyne Limited:**

Bioxyne Limited is an Australian pharmaceutical company focused on the development and commercialization of innovative medicines and active pharmaceutical ingredients. Through its subsidiary, Breathe Life Sciences, Bioxyne is expanding into the production of psychedelic compounds for therapeutic use.

Approved by the Board for release to the ASX.

For further information, please contact:

Bioxyne Limited Investor Relations

Email: info@bioxyne.com Phone: +61 2 9078 8180 Website: www.bioxyne.com







### **About Bioxyne Ltd.**

**Bioxyne Limited (ASX:BXN)** is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

## **About Breathe Life Sciences (BLS)**

**Breathe Life Sciences ("BLS")** is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company's corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, health products, and prescription only cannabis medicines..
- b) Contract drug manufacturing and white label manufacturing of scheduled medicines, therapeutic goods, medical devices, consumer health products, and active pharmaceutical ingredients. BLS manufactures over 200 of Australia's medicinal cannabis brands.
- c) Import, export, and wholesale of active pharmaceutical ingredients, starting materials, patient-ready medicinal products, and/ or consumer health products in Australia, Japan, UK, USA and Europe.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®

United Kingdom: <u>drwatsoncbd.com</u>

UK / EU: breathelifesciences.com

Corporate: bioxyne.com
Australia: bls.com.au

International: breathelifesciences.com

